Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial.

Neal D. Shore; Martin Gleave; Ugo De Giorgi; Antti Rannikko; Christopher M. Pieczonka; Swetha Sridharan; Klaus Brasso; Henry H. Woo; Antonio Gómez Caamaño; Jeff W. Saranchuk; Luke T. Nordquist; Ubirajara Ferreira; Yiyun Tang; Brad Rosbrook; Gabriel P. Haas; Matt Rosales; Fabian Zohren; Jamal Tarazi; Stephen J. Freedland

doi:10.1097/JU.0000000000004961

Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial.

Neal D. Shore
, Martin Gleave
, Ugo De Giorgi
, Antti Rannikko
, Christopher M. Pieczonka
, Swetha Sridharan
, Klaus Brasso
, Henry H. Woo
, Antonio Gómez Caamaño
, Jeff W. Saranchuk
, Luke T. Nordquist
, Ubirajara Ferreira
, Yiyun Tang
, Brad Rosbrook
, Gabriel P. Haas
, Matt Rosales
, Fabian Zohren
, Jamal Tarazi
, Stephen J. Freedland

Department of Urology

1 Citation (Scopus)

Original language	English
Journal	The Journal of urology
Volume	215
Issue number	5
Pages (from-to)	523
Number of pages	1
ISSN	0022-5347
DOIs	https://doi.org/10.1097/JU.0000000000004961
Publication status	Published - 1 May 2026

Access to Document

10.1097/JU.0000000000004961

Cite this

Shore, N. D., Gleave, M., De Giorgi, U., Rannikko, A., Pieczonka, C. M., Sridharan, S., Brasso, K., Woo, H. H., Gómez Caamaño, A., Saranchuk, J. W., Nordquist, L. T., Ferreira, U., Tang, Y., Rosbrook, B., Haas, G. P., Rosales, M., Zohren, F., Tarazi, J., & Freedland, S. J. (2026). Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial. The Journal of urology, 215(5), 523. https://doi.org/10.1097/JU.0000000000004961

Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial. / Shore, Neal D.; Gleave, Martin; De Giorgi, Ugo et al.
In: The Journal of urology, Vol. 215, No. 5, 01.05.2026, p. 523.

Research output: Contribution to journal › Comment/debate › Research › peer-review

Shore, ND, Gleave, M, De Giorgi, U, Rannikko, A, Pieczonka, CM, Sridharan, S, Brasso, K, Woo, HH, Gómez Caamaño, A, Saranchuk, JW, Nordquist, LT, Ferreira, U, Tang, Y, Rosbrook, B, Haas, GP, Rosales, M, Zohren, F, Tarazi, J & Freedland, SJ 2026, 'Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial.', The Journal of urology, vol. 215, no. 5, pp. 523. https://doi.org/10.1097/JU.0000000000004961

@article{c70d38f932c84b4196787214e700565b,

title = "Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial.",

author = "Shore, \{Neal D.\} and Martin Gleave and \{De Giorgi\}, Ugo and Antti Rannikko and Pieczonka, \{Christopher M.\} and Swetha Sridharan and Klaus Brasso and Woo, \{Henry H.\} and \{G{\'o}mez Caama{\~n}o\}, Antonio and Saranchuk, \{Jeff W.\} and Nordquist, \{Luke T.\} and Ubirajara Ferreira and Yiyun Tang and Brad Rosbrook and Haas, \{Gabriel P.\} and Matt Rosales and Fabian Zohren and Jamal Tarazi and Freedland, \{Stephen J.\}",

year = "2026",

month = may,

day = "1",

doi = "10.1097/JU.0000000000004961",

language = "English",

volume = "215",

pages = "523",

journal = "The Journal of urology",

issn = "0022-5347",

publisher = "Wolters Kluwer Health",

number = "5",

}

TY - JOUR

T1 - Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial.

AU - Shore, Neal D.

AU - Gleave, Martin

AU - De Giorgi, Ugo

AU - Rannikko, Antti

AU - Pieczonka, Christopher M.

AU - Sridharan, Swetha

AU - Brasso, Klaus

AU - Woo, Henry H.

AU - Gómez Caamaño, Antonio

AU - Saranchuk, Jeff W.

AU - Nordquist, Luke T.

AU - Ferreira, Ubirajara

AU - Tang, Yiyun

AU - Rosbrook, Brad

AU - Haas, Gabriel P.

AU - Rosales, Matt

AU - Zohren, Fabian

AU - Tarazi, Jamal

AU - Freedland, Stephen J.

PY - 2026/5/1

Y1 - 2026/5/1

UR - https://www.scopus.com/pages/publications/105035418095

U2 - 10.1097/JU.0000000000004961

DO - 10.1097/JU.0000000000004961

M3 - Comment/debate

C2 - 41650344

AN - SCOPUS:105035418095

SN - 0022-5347

VL - 215

SP - 523

JO - The Journal of urology

JF - The Journal of urology

IS - 5

ER -

Reply by Authors: Editorial comment: Treatment of high-risk biochemically recurrentprostate cancer with enzalutamide in combinationwith leuprolide: secondary endpoints from theEMBARK trial.

Access to Document

Other files and links

Cite this